Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 13/20 | 0.42 |
| ▸ | SCN7A | Q01118 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18965793 | 0.91 | MAPT (0.37) | SCN9ATP53GAAMAPT | |
| SCHEMBL18965979 | 0.89 | CYP3A4 (0.43) | — | |
| SCHEMBL17488253 | 0.88 | SCN9A (0.46) | SCN9ASCN7AKCNH2SCN5ASCN10A | |
| SCHEMBL17488249 | 0.83 | NPC1 (0.34) | MAPTLMNA | |
| SCHEMBL17488336 | 0.82 | SCN9A (0.42) | SCN9ASCN7AKCNH2SCN5ALIPE | |
| SCHEMBL18965791 | 0.81 | SCN9A (0.45) | SCN9ASCN7AKCNH2SCN5ATP53 | |
| SCHEMBL17488233 | 0.80 | SCN9A (0.46) | SCN9ASCN7AKCNH2SCN5ASCN10A | |
| SCHEMBL18965788 | 0.79 | P2RX3 (0.40) | TP53LMNA | |
| SCHEMBL17488116 | 0.78 | NPC1 (0.38) | SCN9ASCN7AKCNH2TP53MAPT | |
| SCHEMBL17488131 | 0.78 | MCHR1 (0.41) | SCN9ATP53GAAMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | ALOX5, ALOX15, ALOX12 | SCN9A 2973/4885SCN7A 1309/4885KCNH2 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.